Acquired C1 esterase inhibitor deficiency in lymphomas: prevalence, symptoms, and response to treatment

Abstract We retrospectively studied the prevalence of C1 esterase inhibitor (C1 INH) deficiency in 131 patients with various lymphomas. We determined C1 INH activity, C1 INH antigen, and C4 concentration at diagnosis and after chemotherapy. In follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL) consecutive patients were studied. In these entities, the prevalence of C1 INH deficiency was 10.2% in DLBCL, 4.1% in CLL, and 0% in FL and Hodgkin lymphoma. In indolent lymphomas, we identified only single cases of C1 INH deficiency, predominantly in splenic marginal zone lymphomas (SMZL) (four cases). Only three patients were symptomatic while the majority (11 cases) was asymptomatic. In DLBCL patients who were successfully treated with chemotherapy, complete normalization of C1 INH activity and C4 was observed. In contrast, C1 INH deficiency remained in SMZL patients after splenectomy. We conclude that C1 INH deficiency in lymphomas is frequently asymptomatic and responsive to immunochemotherapy.

[1]  E. Kimby,et al.  Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia , 2015, Haematologica.

[2]  R. Greil,et al.  Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial , 2014 .

[3]  K. Stamatopoulos,et al.  Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma. , 2014, Thrombosis research.

[4]  J. Byrd,et al.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. , 2014, The New England journal of medicine.

[5]  I. Pabinger,et al.  Immune-Mediated Disorders Causing Bleeding or Thrombosis in Lymphoproliferative Diseases , 2014, Seminars in Thrombosis & Hemostasis.

[6]  H. Vestergaard,et al.  Acquired Angioedema - Occurrence, Clinical Features and Associated Disorders in a Danish Nationwide Patient Cohort , 2013, International Archives of Allergy and Immunology.

[7]  U. Jäger,et al.  Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma , 2013, Leukemia & lymphoma.

[8]  J. Cohn,et al.  Ecallantide for treatment of acute attacks of acquired C1 esterase inhibitor deficiency. , 2013, Allergy and asthma proceedings.

[9]  F. Lansigan,et al.  Acquired angioedema and marginal zone lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  É. Oksenhendler,et al.  Acquired C1-Inhibitor Deficiency: 7 Patients Treated with Rituximab , 2012, Journal of Clinical Immunology.

[11]  A. López-Guillermo,et al.  CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. , 2011, The Lancet. Oncology.

[12]  U. Jaeger,et al.  Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. , 2008, The Lancet. Oncology.

[13]  M. Cicardi,et al.  Lymphoproliferative disease and acquired C1 inhibitor deficiency. , 2007, Haematologica.

[14]  M. Cicardi,et al.  Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management. , 2006, Immunology and allergy clinics of North America.

[15]  M. Cicardi,et al.  Angioedema without urticaria: a large clinical survey , 2006, Canadian Medical Association Journal.

[16]  O. Fain,et al.  Déficit acquis en C1 inhibiteur associé à un syndrome lymphoprolifératif : quatre observations , 2004 .

[17]  M. Cicardi,et al.  Autoantibodies and Lymphoproliferative Diseases in Acquired C1-Inhibitor Deficiencies , 2003, Medicine.

[18]  R. Foti,et al.  [Angioedema: first manifestation of non-Hodgkin's lymphoma]. , 2002, Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna.

[19]  W. Tremaine,et al.  Hereditary angioedema: a broad review for clinicians. , 2001, Archives of internal medicine.

[20]  F. Rosen,et al.  Acquired C1 inhibitor deficiency as a result of an autoantibody to the reactive center region of C1 inhibitor. , 1994, Journal of Immunology.

[21]  C. Feighery,et al.  An IgG autoantibody which inactivates C1¯-inhibitor , 1986, Nature.

[22]  V. Eclache,et al.  [Acquired C1 inhibitor deficiency associated with lymphoproliferative disorders: four cases]. , 2004, La Revue de medecine interne.